Efficacy of a Single Dose versus a Multiple Dose Regimen of Mebendazole against Hookworm Infections among School Children: a Randomized Open-label Trial

Tegegne Eshetu, Mulugeta Aemero, Ayalew Jejaw

Tegegne Eshetu
University of Gondar College of Medicine and Health Sciences
teggeoneshetu5@gmail.com Corresponding Author

Mulugeta Aemero
University of Gondar College of Medicine and Health Sciences

Ayalew Jejaw
University of Gondar College of Medicine and Health Sciences

Subject Areas

Infectious Diseases

Keywords

Hookworm, Single Dose, Multiple Dose, Mebendazole, Efficacy
Abstract

Background: Despite the existence of a population-based control program using single dose albendazole or mebendazole as a preventive chemotherapy, hookworm transmission remains high. It causes a negative impact on the growth and school performance of children. In connection to this preventive chemotherapy, different studies produced conflicting results. This study aimed at evaluating the efficacy of single (500mg) versus multiple doses (100mg twice a day during three consecutive days) of mebendazole against hookworm infections among school-aged children.

Methods: This randomized open-label clinical trial took place among school-aged children (6-14 years old) in Burie and Debre Elias towns, Northwest Ethiopia. Using simple randomization, eligible hookworm-positive children were allocated (1:1) to either a single or multiple dose treatment arms. Stool samples were collected and processed using McMaster method at baseline and follow-up period (14-21 days after treatment). Only laboratory technicians were blinded. The cure and egg reduction rates which were assessed after 14-21 days of treatment were the primary and secondary therapeutic outcome measures against hookworm infections, respectively. An independent t-test was used to compare group means, and logistic regression was used to calculate odds ratio (OR). P-value < 0.05 at 95% CI was considered statistically significant.

Result: 108 children, 54 in each treatment arm had completed baseline data and received allocated treatment. 103 children had completed follow-up data records and included for the final efficacy analysis. Cure rate against hookworm was significantly higher in the multiple dose (96.1%) than in the single dose (30.8%) with OR=55.125; 95% CI: 11.92-254.9; P < 0.001. The egg reduction rate in the multiple dose treatment arm (99.5%) was also significantly higher than in the single dose arm (68.9%) with difference t (101) =5.38; 95% CI 230.95-505.36; P < 0.001.

Conclusion: The single dose regimen of mebendazole for the treatment of hookworm infections showed poor cure and egg reduction rates, while the multiple dose revealed satisfactory. Although multiple dose regimen administration is a bit more complex than the single dose, we strongly encourage replacing it with multiple dose regimen during deworming programs in hookworm endemic areas.

Trial registration: This trial is registered in www.pactr.org, # PACTR201911466695052.

Background

Globally, hookworm’s disease burden remains high, and around 500 million people are infected(1). In 2017, the global burden of hookworm infections was estimated at 845,000 disable-adjusted life years (DALYs) (2). This parasite is mainly associated with hypo-albuminemia, iron deficiency anemia, and malnutrition, which cause more subtle chronic health problems like physical and intellectual growth retardation in children, and adverse pregnancy outcomes (3,4). Moreover, it causes annual productivity loses with estimated range of $7.5 billion to $138.9 billion(1). The highest burden and intensity of infections occur in sub-Saharan Africa followed by Asia, Latin America and the Caribbean (5). In sub-Saharan Africa, it has been estimated that 40-50 million school-aged children and 7 million pregnant women are infected (6). In general, over 267 million preschool-aged children and over 568 million school-aged children live in areas where the parasite is intensively transmitted and are in need of treatment and preventive interventions (7).

Currently, control efforts for hookworm infections are implemented through periodic mass drug administration using either of a single dose of albendazole (400mg) or mebendazole (500mg) regimens (8-10). This control measure is implemented without prior information on the infection status of individuals. These days, different studies have revealed conflicting results on the impact of preventive chemotherapy (PC) (4)

In addition to this, multiple studies have shown that, although cheap and widely available, the single dose of mebendazole is unsatisfactorily effective against hookworm infections, with CRs ranging from 18 to 59% (10-15)
A multiple dose (100 mg twice a day over three consecutive days) of mebendazole is among the recommended and widely used anthelminthic regimen for treating hookworm and other soil-transmitted helminthes (STHs) infections throughout the world (16,17). Only a limited numbers of studies were conducted to evaluate the multiple dose efficacies against hookworm infections. The available literature reveals CR ranging from 26% to 97.9% and ERR from 85% to 100% (14,18,19). This inconsistent efficacy status of the drug warrants further studies.

Previously, only one randomized clinical trial comparing the efficacy of the single dose to the multiple dose of mebendazole against hookworm has been conducted(18). However, it is the only randomized clinical trial conducted so far. To contribute to an increase of evidence, we also conducted a clinical trial comparing the single to the multiple dose of mebendazole against hookworm. This study is the first of its kind in Ethiopia.

Methods

Study design

This randomized, open-label clinical trial was conducted at Burie and Debre Elias towns’ primary schools, Northwest Ethiopia, from March to May, 2019. This study included school-aged children aged 6 to 14 years. The study was approved by the Ethical and Review Committee of School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Ethiopia. This trial was retrospectively registered in www.pactr.org, number PACTR201911466695052 on November 26, 2019.

Prior to participant enrolment, all parents/legal guardians’ of the children were informed about the objective, purpose, study procedures, and the potential risk and benefits of participating in the study. Parents/legal guardians who agreed that their child should be enrolled in the study were asked to sign a written informed consent. Verbal assent was also sought from each participant. Parents/legal guardians who were unable to read and write, were asked to give thumbprint after having been read the full informed consent form by a data collector.

Intervention, trial medication, and outcome measures

This randomized clinical trial had two treatment arms: (i) a single dose of mebendazole (500mg) and (ii) a multiple dose of mebendazole (100 mg twice a day for three consecutive days). The multiple dose of mebendazole (WORMIN tab) was commercially obtained from a private pharmacy in the local market, while the single dose of mebendazole (Vermox®) was provided by the local coordinator office of the deworming program. The primary outcome considered was CR against hookworm, while ERR for determining the changes in infection intensity served as a secondary outcome measure 14-21 days of post treatment.

Eligibility criteria and Sample size

Eligible for inclusion were all hookworm-positive children with a signed informed consent who did not have additional health problems (based on medical history, physical examination, vital signs). The following exclusion criteria were also applied: children who received any form of anthelminthic treatment within the past 30 days, were unable to chew the drug (for the single), had diarrhea at the time of the first sampling, had a hemoglobin level <8g/dl, experienced a severe concurrent medical condition or had any known history of allergic reaction to mebendazole, and infected with other parasitic infection. All remaining children were randomized and allocated to one of the two treatment arms.

The desired sample size was determined by using WHO guidelines(20). The local prevalence of hookworm infections was not exactly known, and hence, it was assumed to be 50%. Fifty from each of the two treatment arms would be enough to detect differences in the CR with 80% power using a 2-sided statistical test with alpha-level of 0.05. Moreover, considering a potential loss to follow-up, 20% as a non-response rate was added. Finally, 300 school-aged children were screened for hookworm infections to get the minimum required sample size.
Data collection and Laboratory procedures

Study participants responded to a short questionnaire investigating demographic and other health-related issues using the WHO drug efficacy assessment from. A unique identification number was given to each participant. Then, each participant received a sterile stool container labeled with his/her unique identification number and was asked to provide approximately 10mg of fresh stool. All children were well informed on how to avoid any contamination of the sample. Samples were immediately transported to the nearby health center laboratory in Debre Elias and Burie hospital laboratory.

The McMaster concentration technique, which is the standard reference method for evaluating drug efficacy in Veterinary Parasitology and has recently been evaluated for human helminthes, was used for this study(20,21). Laboratory quality control was performed by an expert microscopist by re-reading 10% of slides of each laboratory technician. Only one stool sample was collected from each participant at baseline and follow-up.

Upon completion of all the baseline parasitological and participant information survey, hookworm-positive children were subjected to a physical and clinical examination by a senior health officer. Height was measured with a standard meter (to the nearest 0.1 cm), and weight with an electronic balance (to the nearest 0.1 kg). Haemoglobin levels were measured in capillary blood using the finger-prick method (HemoCue®301). Children who were found positive for *Ascaris lumbricoides* and *Trichuris trichiura* were treated with albendazole (400mg) during baseline screening.

Randomization

Using simple randomization lottery techniques, eligible hookworm-positive children were randomly assigned either to the single (500mg) or multiple dose regimen of mebendazole (100 mg twice a day for three consecutive days) arm with a 1:1 ratio. Eligible children were randomly assigned and allocated to each treatment arm by the researcher. The drug administrator and children were not masked for drug treatment. Only laboratory technicians were blinded to the dose allocation, hypothesis and objective of the study.

Drug administration

A slice of biscuit was given to each eligible child before drug administration. The single dose and the first dose of the multiple dose of mebendazole regimens were administered to each randomized child in front of their parents by the research team and public health officer at school. After administering the drug, children in the single dose were monitored for 3 to 4 hours to observe if any vomiting and other adverse events were occurred following treatment. In the case of children who were randomized into multiple dose arm; parents/guardians were convinced to take home the remaining tablets in a sealed envelope and were instructed on how to administer the drugs. They were instructed to give the drug twice a day (every morning and evening for three days), avoid skipping/doubling any dose, follow strictly their child up to the end of treatment and study participants had been reminded not to drink alcohol on treatment days. Participants/parents/guardians were informed to report any medical discomfort following treatment to the investigators or the nearby health extension worker.

Follow-up data collection

Each treated child was revisited 14-21 days after drug administration and asked to provide one stool sample for the second time. At this time point, children were also asked about the occurrence of vomiting and diarrhea following drug administration.

A participant who vomited within 4 hours after drug administration or a participant with diarrhea was excluded for the final analysis. The same laboratory procedures took place at the follow-up. Children who remained infected with hookworm or other STH were treated with albendazole (400mg) at the end of the study.

Statistical analysis

Data was entered to Epi-data software to check data completeness and clearance, and then transferred to SPSS version-23 for statistical analysis. All analyses were performed on a per-protocol basis. Only children with complete data sets were included in the analysis to determine the treatment efficacy. The baseline
Characteristics of the study participants are summarized using frequencies, mean and standard deviation (table 1). Infection intensity with hookworm was grouped in to light, moderate and heavy infections, according to WHO guidelines (22). Cure and egg reduction rates were used to assess the efficacy of the drug. Cure rate was assumed to be the proportion of individual hosts positive for hookworm who become parasitologically negative after treatment (23). Egg reduction rate was defined as the relative reduction in the mean egg output after treatment compared to pre-treatment value (24). ERR was expressed using both the arithmetic mean (AM) and the geometric mean (GM) (25).

Confidence intervals for ERR were calculated using bootstrap re-sampling method with 5000 iterations.

An independent t-test was used to compare group means, whereas CRs were compared by calculated Odds Ratio (OR) using logistic regression. For all statistical analyses a \textit{P-value} of 0.05 was considered as the limit for statistical significance.

**Result**

A total of 300 school-aged children were enrolled in the baseline screening. Of these, 120 (40%) (64 females and 56 males) were found to be hookworm-positive. Eleven hookworm infected children were excluded because they were absent from school on the clinical and physical examination day. From 109 randomized children, one child from the single dose of mebendazole arm was not willing to receive the allocated treatment. Thus, 108 eligible children, 54 in each treatment arm had completed baseline data and received allocated treatment. 14 to 21 days of post treatment, follow up sample collection was performed with a seven day time frame. During this time, two participants in the single dose and one child in the multiple dose arms were absent from school and two children in the multiple dose arm were unable to provide sufficient stool samples. Finally, a total of 103 children had complete data records, 52 in single dose and 51 in multiple dose mebendazole arm were included for the final efficacy analysis (Figure 1).

Baseline survey

At baseline, the eligible children allocated in the two treatment groups were comparable in terms of several characteristics. The mean age in single dose group was 10.78 ± 2.1 years and 10.48 ± 1.34 years in the multiple dose group. The mean weights of participants for single and multiple doses were 31.45 ± 7.96 and 29.69 ± 6.2 kg, respectively. Moreover, most participants were diagnosed with light hookworm infections (see table 1).

Table 1: Baseline characteristics of randomized children, at Burie and Debre Elias towns, North West Ethiopia, January - June 2019.
Table 1. Baseline characteristics and baseline EPG of single and multiple dose arms

|                          | Single dose (N=52) | Multiple dose (N=51) |
|--------------------------|--------------------|----------------------|
| **Sex**                  |                    |                      |
| Male                     | 17 (32.7%)         | 28 (54.9%)           |
| Female                   | 35 (67.3%)         | 23 (45.1%)           |
| **Mean (SD) age, year**  |                    |                      |
|                          | 10.78 (2.1)        | 10.48 (1.34)         |
| **Mean (SD) weigh, kg**  |                    |                      |
|                          | 31.45 (7.96)       | 29.69 (6.2)          |
| **Mean (SD) height, m**  |                    |                      |
|                          | 1.35 (0.13)        | 1.34 (0.08)          |
| **Mean (SD) haemoglobin, g/dl** |             |                      |
|                          | 13.8 (1.09)        | 14.02 (0.93)         |

**Baseline EPG**

|                          | Single dose (N=52) | Multiple dose (N=51) |
|--------------------------|--------------------|----------------------|
| Arithmetic mean (95% CI) | 1216.35 (845.84-1586.86) | 1134.3 (864.4-1404.2) |
| Geometric mean (95% CI)  | 826.1 (651.5-1039.7)  | 821.3 (656.3-1024)   |

**Infection intensity**

|                          | Single dose (N=52) | Multiple dose (N=51) |
|--------------------------|--------------------|----------------------|
| Light (1-1999 EPG)       | 43 (82.7%)         | 45 (88.2%)           |
| Moderate (2000-3999)     | 7 (13.5%)          | 5 (9.8%)             |
| Heavy (>=4000)           | 2 (3.8%)           | 1 (2%)               |

SD = standard deviation

Efficacy of multiple and single dose regimen of mebendazole for treating hookworm infections

The follow-up fecal egg intensity of hookworm in terms of arithmetic mean were 378.04 EPG and 5.88 EPG in the single and multiple dose arms, respectively. Cure rates of the single and multiple dose regimens of mebendazole for treating hookworm infection were 30.8% (19.2 - 44.2%) and 96.1% (90.2-100%), respectively. In addition, the ERRs in arithmetic mean were 68.9% in the single dose and 99.5% in the multiple dose arms. The ERR in geometric mean were 82.2%. Overall, 36 (69.2%) school-aged children who were treated with single dose and two (3.9%) treated with multiple dose mebendazole remained hookworm-egg positive at follow-up (see table 2).

There was a substantial difference for both CR and ERR between multiple and single dose regimen of mebendazole for treating hookworm infections [(CR: 96.1% versus 30.8%; OR=55.125; 95% CI: 11.92-254.9; p < 0.001); (ERR= 99.5% versus 68.9%; 95% CI 230.95-505.36; p <0.001)].


Table 2: Cure and egg reduction rates of single and multiple dose mebendazole against hookworm infections among school-aged children from Burie and Debre Elias towns, January – June 2019

|                           | Single dose                        |
|---------------------------|------------------------------------|
| No. of Infections before treatment (%) | 52 (100%)                          |
| No. of cured after treatment | 16                                 |
| CR (95% CI)               | 30.8 (19.2-44.2)                   |
| EPG arithmetic mean       |                                    |
| Before treatment (95% CI) | 1216 (845.8-1586.86)               |
| After treatment (95% CI)  | 378.04 (237.1-510.99)              |
| ERR (95% CI)              | 68.9% (48.07-73.14)                |
| EPG geometric mean        |                                    |
| Before treatment (95% CI) | 826.1 (651.1-1039.7)               |
| After treatment (95% CI)  | 61.3 (27.8-133.0)                  |
| ERR (95% CI)              | 92.6% (87.5-96.4)                  |
| Infection intensity after treatment | N (%)                              |
| Light (1-1999 EPG)        | 35 (67.1%)                         |
| Moderate (2000-3999)      | 1 (1.9%)                           |
| Heavy (>=4000)            | -                                  |

Discussion

Ethiopia is a hotspot area for hookworm and other STH infections. School children are disproportionately affected by these parasites(6, 26). Mass drug administration for selected risk groups, such as children, using a single dose of albendazole or mebendazole is the mainstay for the control of STHs in Ethiopia(27). However, there are recent reports which showed a reduction of the efficacy of the single dose mebendazole efficacy in some endemic areas (12,18,28,29). Moreover, an increased use of the single dose of mebendazole in many endemic areas may lead to the developments of drug resistance. Thus, perhaps other regimens of the drug could increase its efficacy. This calls for continuous monitoring of its therapeutic efficacy.

So far, few studies have investigated the efficacy of the multiple dose of mebendazole against hookworm
infections (18,30,31). The present study showed that a multiple dose of mebendazole (CR= 96.1%, CI: 90.2 to 100) is significantly more efficacious at clearing hookworm infections than the single dose (CR= 30.8%, CI: 19.2-44.2) with OR=55.125; 95% CI: 11.92-254.9; P<0.001. Almost all hookworm-infected children were cured following multiple dose of mebendazole treatment. Our results are in line with the only head to head comparative randomized controlled trial study, which revealed superiority of the efficacy status of the multiple dose over the single dose mebendazole(18).

On the other hand, the therapeutic efficacy of the multiple dose in the current study is considerably higher than those previously reported in Iran(CR = 35% & ERR= 40.83%) (31) and Brazil (CR = 58.5%)(30). This inconsistency in efficacy results could be related to the use of different diagnostic techniques, the sample size variation, the age of study participants, the parasite genetic diversity, and the study site. For instance, the study conducted in Iran applied the Stoll diagnostic technique, whereas the study in Brazil used the duplicated Kato-Katz and Hoffmann’s spontaneous sedimentation techniques. Thus, variation in the sensitivity of the diagnostic techniques might be the possible source for the discrepancies.

Studies have been conducted to assess the efficacy of the single dose of mebendazole on hookworm infections (18,19,28,29,32–34). Overall, their CRs ranged from 7.6% to 70.3% and ERRs ranged from 52% to 76.3%. The CR of the single dose in our trial was 30.8% (CI 19.2 to 44.2%) and the ERR was 68.9% (CI 48.1 to 73.1%). This is in line with studies conducted in China (CR= 29%)(28), Vietnam (CR= 38% & ERR= 52%) (19), and Tanzania (CR=24.4 & ERR= 59.5%)(33). However, it does not agree with other studies conducted in Zanzibar (CR= 7.6%) (29), Tanzania (CR= 13%)(18), Lao PDR (CR= 17.6% & ERR= 76.3%)(34), and Cameroon (CR= 70.3%)(32). The above mentioned reasons could also have resulted in the discrepancies.

Lower efficacy of the single dose compared to the multiple doses of mebendazole might be associated with the extensive and frequent use of the single dose in deworming program. Although administration of the single dose of mebendazole for mass treatment is convenient in terms of practical implementation, our findings reveal that its capacity to achieve its primary objective of preventive chemotherapy on intensity reduction is questionable. In other words, 43 (82.7%), of the infected study participants were under light infection category at the base line, and 35 (67.1%) remained in this category after treatment (Table 2).

The administration of multiple doses of mebendazole as mass chemotherapy seems to be complex and the cost of administration is likely to be higher. However, our results strongly encourage its use as a preventive and control measure in hookworm endemic areas. In addition, this tangible efficacy variation in our trial also indicating new option for administering a multiple dose of mebendazole regimen in the prevention and control programs through handing the drugs to teachers or parents as we did in this trial in order to minimize the cost and other logistic issues.

Although comparing the two commonly used dose of mebendazole in a head to head manner is considered as strength of our study, the infection intensity of the parasite was determined by the examination of a single stool sample. Also, the multiple dose of mebendazole was administered by caregiver of each participant and the tablets might be not administered as recommended. This might have affected our findings which should be interpreted with these limitations in mind.

Overall, the multiple dose regimen of mebendazole showed satisfactory efficacy with significantly higher CR and ERR than the single dose regimen, against hookworm infections in school-aged children. These results advocate a need to revise treatment guidelines of the current deworming programs, particularly in hookworm endemic areas. Moreover, we recommend conducting further studies using a larger sample size, more sensitive diagnostic procedures and in different regions of the globe.

Abbreviations

AM: Arithmetic Mean; BZ: Benzimidazole; CI: Confidence Interval; CR : Cure Rate; DALYs: Disable Adjusted Life Years; EPG: Geometric Mean (GM); Egg per Gram; ERR: Egg Reduction Rate; OR: Odds
Declarations

Authors’ contributions

TE conceptualized the study, contributed to the format of the data collection instruments, analysis, and write up of the first draft manuscript. MA contributed to the study protocol, development of the data collection tools field data collection and analysis. AJZ was involved in the proposal development and data analysis. All authors critically reviewed and approved the final manuscript.

Acknowledgments

We would like to acknowledge University of Gondar for funding the project. Moreover, we would like to extend our gratitude to East Gojjam Zonal health offices, study participants, and data collectors.

Competing interests

The authors declare that they have no competing interests.

Availability of Data and Materials

The data generated or analyzed during this study is included in this manuscript. Other data will be available from the corresponding author upon request.

Consent for publication

Not applicable

Ethics approval and consent to participate

Ethical clearance was obtained from Ethical and Review Committee of School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences University of Gondar, Ethiopia. A permission and support letters were also obtained from Zonal Health bureau and District Health Office. Besides, written informed consent was secured from each participant parent/guardian.

Funding

This study was fully granted by University of Gondar.

This fund was provided only for covering and supports us in the expense of the thesis work. The funding body has no any other role regarding to the study design, date collection, analysis, interpretation, and manuscript write up.

Authors’ detail

1Department of Medical parasitology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. P.O.Box: 196

References

1. Bartsch SM, Hotez PJ, Asti L, Zapf KM, Bottazzi ME, Diemert DJ, et al. The Global economic and health burden of human hookworm infections. *PLoS Negl Trop Dis.* 2016 Sep 8; 10(9):e0004922.
2. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for
195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1859–922.

3. Hossain M, Bhuiyan MdJuddin. Hookworm Infection: A Neglected Tropical Disease of Mankind. J Infect Mol Biol. 2016; 4(2):24.

4. Freeman MC, Akogun O, Belizario V, Brooker SJ, Gyorkos TW, Intiaz R, et al. Challenges and opportunities for control and elimination of soil-transmitted helminth infection beyond 2020. PLoS Negl Trop Dis. 2019; 13(4):e0007201.

5. Weller PF, Karin Leder. Hookworm infection. UpToDate. 2019 Sep 20.

6. Hotez PJ, Kamath A. Neglected Tropical Diseases in Sub-Saharan Africa: Review of Their Prevalence, Distribution, and Disease Burden. PLoS Negl Trop Dis. 2009; 3(8):e412.

7. World Health Organization. Soil-transmitted helminth infections. 2018. Available from: http://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections

8. Hotez PJ, Bethony J, Bottazzi ME, Brooker S, Buss P. Hookworm: “The Great Infection of Mankind.” PLoS Med. 2005; 2(3):e67.

9. Loukas A, Hotez PJ, Diemert D, Yazdanbakhsh M, McCarthy JS, Correa-Oliveira R, et al. Hookworm infection. Nat Rev Dis Primer. 2016; 2:16088.

10. Mrus J, Baeten B, Engelen M, Silber SA. Efficacy of single-dose 500 mg mebendazole in soil-transmitted helminth infections: a review. J Helminthol. 2018; 92(03):269–78.

11. Brooker SJ. Soil-transmitted helminth treatment: multiple-drug regimens. Lancet Infect Dis. 2018; 18(7):698–9.

12. Soukhathammanyong PA, Sayasone S, Phongluxa K, Xayaseng V, Utzinger J, Vounatsou P, et al. Low Efficacy of Single-Dose Albendazole and Mebendazole against Hookworm and Effect on Concomitant Helminth Infection in Lao PDR. Prichard RK, editor. PLoS Negl Trop Dis. 2012; 6(1):e1417.

13. Speich B, Moser W, Ali SM, Ame SM, Albonico M, Hattendorf J, et al. Efficacy and reinfection with soil-transmitted helminths 18-weeks post-treatment with albendazole-ivermectin, albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole. Parasit Vectors. 2016; 9(1).

14. Steinmann P, Utzinger J, Du Z-W, Jiann C-Y, Chen J-X, Hattendorf J, et al. Efficacy of Single-Dose and Triple-Dose Albendazole and Mebendazole against Soil-Transmitted Helminths and Taenia spp.: A Randomized Controlled Trial. PLoS ONE. 2012; 6(9):e25003.

15. Dormy P, Behnke J, Sacko M, Vercruysse J, De Clercq D, Gilbert F. Failure of Mebendazole in Treatment of Human Hookworm Infections in the Southern Region of Mali. Am J Trop Med Hyg. 1997; 57(1):25–30.

16. Food, Medicine and Healthcare Administration and Control Authority of Ethiopia. List of Essential Medicines for Ethiopia. World Health Organ Resour. 2010; Available from: http://apps.who.int/medicinedocs/en/m/abstract/Js17568en/.

17. WHO. WHO Model Prescribing Information: Drugs Used in Parasitic Diseases. Geneva: World Health Organ; 1995.

18. Palmeirim MS, Ame SM, Ali SM, Hattendorf J, Keiser J. Efficacy and Safety of a Single Dose versus a Multiple Dose Regimen of Mebendazole against Hookworm Infections in Children: A Randomised, Double-blind Trial. EClinicalMedicine. 2018; 1:7–13.

19. Flohr Carsten, Luc Nguyen Tuyen, Sarah Lewis, Truong Tan Minh, Jim Campbell, John Britton, et al. Low Efficacy of Mebendazole against Hookworm in Vietnam: two randomized controlled trials. Am Soc Trop Med Hyg. 2007; 76(4):732–6.

20. World Health Organization. Assessing the Efficacy of Anthelminthic Drugs Against Schistosomiasis and Soil-Transmitted Helminthiases. World Health Organ; 2013.

21. Levecke B, Behnke JM, Ajampur SSR, Albonico M, Ame SM, Charlier J, et al. A Comparison of the Sensitivity and Fecal Egg Counts of the McMaster Egg Counting and Kato-Katz Thick Smear Methods for Soil-Transmitted Helminths. PLoS Negl Trop Dis. 2011; 5(6):e1201.

22. World Health Organization. Soil-transmitted helminthiases: eliminating soil-transmitted helminthiases as a public health problem in children progress Report 2001-2010 and strategic plan 2011-2020.WHO; 2012.

23. Walker M, Mabud TS, Olliaro PL, Coulibaly JT, King CH, Raso G, et al. New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel. Parasit Vectors. 2016; 9(1).

24. Moser W, Keiser J, Speich B, Sayasone S, Knopp S, Hattendorf J. One mean to rule them all? The
arithmetic mean based egg reduction rate can be misleading when estimating anthelminthic drug efficacy in clinical trials. *PLoS Negl Trop Dis.* 2020;14(4):e0008185.

25. Vercruysse J, Behnke JM, Albonico M, Ame SM, Angebault C, Bethony JM, et al. Assessment of the Anthelminthic Efficacy of Albendazole in School Children in Seven Countries Where Soil-Transmitted Helminths Are Endemic. *PLoS Negl Trop Dis.* 2011;5(3):e948.

26. Deribe K, Meribo K, Gebre T, Hailu A, Ali A, Aseffa A, et al. The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination. *Parasit Vectors.* 2012;5(1):240.

27. Jozef Vercruysse, Marco Albonico, Jerzy Behnke, Andrew Kotze, James McCarthy, Roger Prichard, et al. Monitoring Anthelminthic Efficacy for Soil Transmitted Helminths (STH). *WHO;* 2008;

28. Steinmann P, Utzinger J, Du Z-W, Jiang J-Y, Chen J-X, Hattendorf J, et al. Efficacy of Single-Dose and Triple-Dose Albendazole and Mebendazole against Soil-Transmitted Helminths and Taenia spp.: A Randomized Controlled Trial. *PLoS ONE.* 2011;6(9):e25003.

29. Albonico M, Bickle Q, Ramsan M, Montresor A, Savioli L, Taylor M. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. *Bull World Health Organ.* 2003;81:343-52.

30. Zani LC, Favre TC, Pieri OS, Barbosa CS. Impact of antihelminthic treatment on infection by Ascaris lumbricoides, Trichuris trichiura and hookworms in Covas, a rural community of Pernambuco, Brazil. *Rev Inst Med Trop São Paulo.* 2004;46(2):63–71.

31. Farahmandian I, Arfaa F, Jalali H, Reza M. Comparative Studies on the Evaluation of the Effect of New Anthelmintics on Various Intestinal Helminthiasis in Iran. *Chemotherapy.* 1977;23(2):98–105.

32. Payne V, Megwi L, Noubom M, Yamsssi C, Ngangnang G, Mbida M, et al. Efficacy of Single Dose of 500 mg Mebendazole on Geohelminths amongst School Age Children in Bafoussam, Cameroon. *Br Microbiol Res J.* 2016;12(2):1–9.

33. Speich B, Ali SM, Ame SM, Bogoch II, Alles R, Huwyler J, et al. Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. *Lancet Infect Dis.* 2015;15(3):277–84.

34. Soukhathammavong PA, Sayasone S, Phongluxa K, Xayaseng V, Utzinger J, Vounatsou P, et al. Low Efficacy of Single-Dose Albendazole and Mebendazole against Hookworm and Effect on Concomitant Helminth Infection in Lao PDR. *PLoS Negl Trop Dis.* 2012;6(1):e1417.
Screened for eligibility (N = 300)

Microscopically hookworm positive (n = 120)
- Eligible
  
  Excluded (n = 11)
  Absent during treatment time

Microscopically hookworm negative
- Not eligible
  
  Randomized (n = 109)

Allocated to single dose mebendazole (n = 55)
- 54 received allocated intervention

Allocated to multiple dose mel 54)
Figure 1
Flow chart for identification procedures of eligible children.